Sort
48,018 grants matching “immunotherapy”
Targetable epigenetic and transcriptional mechanisms in melanoma that shape the microenvironment
$1,461,713David E Fisher · Massachusetts General Hospital · P01 · FY2021 · CA
Immunotherapy of low grade lymphoid malignancies
$1,461,574Adrian U Wiestner · National Heart, Lung, And Blood Institute · ZIA · FY2021 · HL
Search for the Structural Basis of Biomacromolecular Function and Activity
$1,461,295Yun Xing M Wang · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
Mechanisms Underlying Clearance of Persistent Infections and Tumors
$1,461,102Dorian McGavern · National Institute Of Neurological Disorders And Stroke · ZIA · FY2024 · NS
Overcoming resistance to BRAF(V600E) targeted therapies in melanoma
$1,460,954David E Fisher · Massachusetts General Hospital · P01 · FY2013 · CA
A Phase 1-2 clinical program for the teatment of Microsatellite Stable Colorectal Cancer with the combination of SR-8541A, Botensilimab, and Balstilimab
$1,460,952Mohan Rao Kaadige · Stingray Therapeutics, Inc. · R44 · FY2025 · CA
DEVELOPMENT AND VALIDATION OF AN EPIGENOMIC LANDSCAPE AND NOVEL IMMUNOTHERAPY IN PROSTATE CANCER DISPARITIES
$1,460,695The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. · · FY2025 · Defense Health Agency
Innate inflammatory responses during pulmonary infections
$1,460,145Katrin Mayer-Barber · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI
Programming cellular behavior by mechanical forces
$1,460,119Julien Berro · Yale University · R01 · FY2025 · EB
Functions and Mechanisms of NF-kB Factors and their Regulators
$1,459,824Philip Murphy · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
A Phase II Controlled Trial of Allogeneic Mesenchymal Stromal Cells for the Treatment of Refractory Lupus (MiSLE)
$1,459,720Gary S. Gilkeson · Medical University Of South Carolina · U01 · FY2025 · AI
Immunobiology and Immunotherapy of Pediatric Tumors
$1,459,080Crystal Mackall · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA
Immune Function and the Progression to Type 1 Diabetes
$1,458,398Mark A Atkinson · University Of Florida · P01 · FY2016 · AI
Harnessing natural killer cells for cellular immunotherapy against solid tumors
$1,457,050Wilfredo F Garcia-Beltran · Massachusetts General Hospital · DP2 · FY2025 · CA
Coordinating center for the NCI small cell lung cancer research consortium
$1,456,493Charles M Rudin · Sloan-Kettering Inst Can Research · U24 · FY2024 · CA
Clinical development of mechanism-based lymphoma therapies
$1,454,350Louis Staudt · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
THERAPY OF HIV WITH GENETICALLY MODIFIED T CELL CLONES
$1,454,188Fred Hutchinson Cancer Research Center · P01 · FY2001 · AI
A "Trojan Horse" bispecific antibody strategy for broad filovirus therapeutics
$1,452,650Kartik Chandran · Albert Einstein College Of Medicine, Inc · R01 · FY2017 · AI
Innate inflammatory responses during pulmonary infections
$1,451,320Katrin Mayer-Barber · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI
Basic Research Support for the CCR
$1,450,621Robert Wiltrout · Division Of Basic Sciences - Nci · ZIC · FY2010 · CA
DCTD Biopharmaceutical Development - Type 1 Diabetes RAID projects
$1,450,000Larry Arthur · Science Applications International Corp · N01 · FY2009 · CA
UCLA SPORE in Prostate Cancer
$1,449,094Robert E Reiter · University Of California Los Angeles · P50 · FY2020 · CA
AIDS CLINICAL TRIALS UNIT
$1,448,316University Of Pennsylvania · U01 · FY2004 · AI
Cellular & Inflammatory Pathways in Ashtma & Allergic Diseases: From IgE to Cells
$1,445,204Lawrence Barry Schwartz · Virginia Commonwealth University · U19 · FY2010 · AI
Cancer Biomaterials Engineering
$1,444,994Matthew Wolf · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA